Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2024-06-04 Regulatory Filings
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience announcing a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) with the Public Procurement Service of South Korea. This is a standard material event disclosure regarding a commercial contract. Since it does not fit into specific categories like M&A (TAR) or capital changes (SHA), and is a standard regulatory disclosure of a business event, it falls under the general regulatory filing category.
2024-06-04 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 1% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) for SK Bioscience, which is a mandatory annual regulatory filing in South Korea for companies belonging to large business groups (chaebols). It contains detailed information on company structure, financial status, board composition, shareholding, and inter-company transactions. This type of filing is a standard regulatory requirement under the Fair Trade Commission (FTC) regulations in Korea and falls under the 'Regulatory Filings' category as it is a specific statutory disclosure that does not fit into the other specialized categories like 10-K or IR.
2024-05-31 Korean
기업지배구조보고서공시
Governance Information Classification · 1% confidence The document is a 'Corporate Governance Report' (기업지배구조보고서) for SK Bioscience. It details the company's governance structure, board composition, shareholder rights, and internal control policies. In the context of financial reporting, this type of document is classified under Governance Information (CGR), as it specifically addresses the company's internal rules, board structure, and governance practices as required by regulatory standards.
2024-05-31 Korean
투자판단관련주요경영사항 (COVID-19 백신 스카이코비온(GBP510)의 영국 MHRA 품목허가(Marketing Authorisation) 취하 결정)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the withdrawal of a marketing authorization for their COVID-19 vaccine in the UK. It is a specific corporate disclosure filed with the Korea Exchange (KRX) under the 'Major Management Matters' category. Since it does not fit into specific categories like M&A, dividends, or share issues, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2024-05-17 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for SK Bioscience, covering the period from 2024.01.01 to 2024.03.31. It contains detailed financial data, business operations, management discussion, and research and development activities. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean
투자판단관련주요경영사항 (COVID-19 백신 스카이코비원 세계보건기구(WHO) 긴급사용목록(Emergency Use Listing) 등재 철회 결정)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding a material management decision (withdrawal of WHO Emergency Use Listing for their COVID-19 vaccine). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filings in the Korean market. Since it is a specific regulatory announcement regarding a business strategy change and does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2024-05-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.